Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Apr 08, 2023 8:41pm

118 Views

Post# 35385545

ARCH $4,000,000 funding from the National Research Council

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program.

These include:

dose escalation studies;
costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial;
manufacturing new drug product supply to support future non-COVID human trials;
the non-COVID Phase II trials (such as a cardiac surgery associated acute kidney injury trial) to gather more human data to support future drug approval;
and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide.